This company has been acquired
Entasis Therapeutics Holdings Crecimiento futuro
Future controles de criterios 2/6
Información clave
52.3%
Tasa de crecimiento de los beneficios
52.0%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Biotechs | 20.9% |
Tasa de crecimiento de los ingresos | 67.6% |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | Low |
Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Will Entasis Therapeutics Holdings (NASDAQ:ETTX) Spend Its Cash Wisely?
Dec 16Entasis Therapeutics: AstraZeneca Spin-Out Developing Targeted Antibacterial Products
Nov 17Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?
Aug 19Entasis Therapeutics shares rise after lining up ETX0462 poster presentation
Jun 18What Kind Of Shareholders Own Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX)?
Feb 17Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?
Dec 01Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2024 | 32 | -35 | -42 | -38 | 2 |
12/31/2023 | 8 | -60 | N/A | -53 | 2 |
12/31/2022 | N/A | -61 | N/A | -56 | 3 |
3/31/2022 | N/A | -52 | -47 | -47 | N/A |
12/31/2021 | N/A | -47 | -43 | -43 | N/A |
9/30/2021 | N/A | -46 | -38 | -38 | N/A |
6/30/2021 | N/A | -45 | -39 | -39 | N/A |
3/31/2021 | N/A | -46 | -42 | -42 | N/A |
12/31/2020 | N/A | -50 | -45 | -45 | N/A |
9/30/2020 | N/A | -54 | -46 | -46 | N/A |
6/30/2020 | 7 | -46 | -43 | -43 | N/A |
3/31/2020 | 7 | -46 | -48 | -48 | N/A |
12/31/2019 | 7 | -44 | -45 | -45 | N/A |
9/30/2019 | 7 | -38 | -45 | -45 | N/A |
6/30/2019 | N/A | -52 | -43 | -43 | N/A |
3/31/2019 | 5 | -44 | -34 | -33 | N/A |
12/31/2018 | 5 | -42 | -36 | -36 | N/A |
9/30/2018 | 5 | -43 | -34 | -33 | N/A |
6/30/2018 | 5 | -34 | -33 | -33 | N/A |
3/31/2018 | N/A | -35 | -34 | -34 | N/A |
12/31/2017 | N/A | -30 | -27 | -27 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. tasa de ahorro: ETTX is forecast to remain unprofitable over the next 3 years.
Beneficios frente mercado: ETTX is forecast to remain unprofitable over the next 3 years.
Beneficios de alto crecimiento: ETTX is forecast to remain unprofitable over the next 3 years.
Ingresos vs. Mercado: ETTX's revenue (67.6% per year) is forecast to grow faster than the US market (8% per year).
Ingresos de alto crecimiento: ETTX's revenue (67.6% per year) is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
Futura rentabilidad financiera (ROE): Insufficient data to determine if ETTX's Return on Equity is forecast to be high in 3 years time